

This announcement is for informational purposes only and is not an offer to buy or sell or the solicitation of an offer to buy or sell securities in the United States or in any other jurisdiction in which such offer or solicitation would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Neither this announcement nor anything herein forms the basis for any contract or commitment whatsoever. Neither this announcement nor any copy hereof may be taken into or distributed in the United States. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the United States Securities Act of 1933. Any public offering of securities to be made in the United States will be made by means of a prospectus. Such prospectus will contain detailed information about the company making the offer and its management, as well as financial statements. No public offering of securities is to be made by the Issuer or the Guarantor (as defined below) in the United States.

**Dr.Peng Holding Hongkong Limited**  
**(鵬博士投資控股香港有限公司)**  
*(incorporated in Hong Kong with limited liability)*

**US\$500,000,000 in aggregate principal amount of 2.50% (formerly 5.05% from 1 June 2017 up to (but excluding) 1 June 2020 and 7.55% from 1 June 2020 up to (but excluding) 1 December 2021) guaranteed senior notes originally due 2020, extended to 2022 and further extended to 2025**

(Global Note Certificate ISIN: XS1611011922, Common Code: 161101192)  
(the “Notes”)

**Announcement - Launch of Consent Solicitation**

Unless otherwise defined in this announcement, capitalised terms used in this announcement have the same meaning as given to them in the relevant amended and restated trust deed constituting the Notes (the “**Trust Deed**”).

The Issuer today published a notice of meeting of the holders of the Notes (the “**Notice of Meeting**”) for the purposes of convening a meeting of the holders of the Notes to be held on 13 February 2023 at which the holders of the Notes will be asked to consider and, if thought fit, to approve certain resolutions which will be proposed as an Extraordinary Resolution (as defined in the Trust Deed) for the purposes of modifying certain terms and conditions of the Notes and proposing waivers. The detailed terms of the Extraordinary Resolution are described in the Notice of Meeting.

The Issuer encourages the Noteholders to participate in the consent solicitation (the “**Solicitation**”) and looks forward to Noteholders support of the proposal to ensure the long-term success of the Group for the benefit of the Noteholders and other stakeholders.

Noteholders who have submitted a valid Consent Instruction with respect to the Notes they hold in favour of the Extraordinary Resolution prior to 5:00 p.m. (CET) on 8 February 2023 (or, if earlier, before the expiration time and/or expiration date set by the relevant Clearing System), and who have not subsequently validly withdrawn their Consent Instruction or otherwise made arrangements to vote against, attend the meeting in person or abstain from voting in respect of the Extraordinary Resolution, will be entitled to receive the amount of US\$2.50 per US\$1,000 in outstanding principal amount of the Notes (as adjusted by the Clearing System Pool Factor (as defined below)) in respect of which it has so submitted its Consent Instruction. Noteholders who attend the Meeting in person will not be entitled to receive the Consent Fee even if they vote in favour of the Extraordinary Resolution.

The aggregate principal amount of the Notes outstanding as of the date of this Announcement is US\$244,751,825. A pool factor of 57.95% currently applies to Notes held through the Clearing Systems such that the outstanding principal amount of Notes corresponds to the pool factor multiplied by the nominal amount of Notes shown in the records of the Clearing Systems (the “**Clearing System Pool Factor**”).

The Solicitation is being made by the Issuer solely pursuant to the Notice of Meeting and related materials. Holders of the Notes should read the Notice of Meeting and related materials (including the consent solicitation memorandum

(the “**Consent Solicitation Memorandum**”)), carefully prior to making any decision with respect to the Solicitation because they contain important information.

The Issuer has retained Morrow Sodali Ltd to act as information agent and as tabulation agent for the Solicitation (the “**Information and Tabulation Agent**”). Requests for documents and questions regarding the Solicitation process may be directed to Morrow Sodali Ltd and questions regarding the proposed amendments to the terms of the Notes may be directed to the Issuer through Morrow Sodali Ltd. Certain documents related to the Solicitation, including the Notice of Meeting and the Consent Solicitation Memorandum are available on the Consent Website (<https://projects.morrowsodali.com/drpeng>), subject to eligibility confirmation and registration. The Information and Tabulation Agent for this Solicitation can be contacted as follows:

#### **INFORMATION AND TABULATION AGENT**

Morrow Sodali Ltd  
Hong Kong: The Hive, 33-35 Hillier St, Sheung Wan  
London: 103 Wigmore Street, W1U 1QS  
Phone: +852 2319 4130 (Hong Kong) and +44 20 4513 6933 (London)  
Attention: Debt Services Team  
Email: [DrPeng@investor.morrowsodali.com](mailto:DrPeng@investor.morrowsodali.com)  
Consent Website: <https://projects.morrowsodali.com/drpeng>

**Investors are reminded to exercise caution when dealing in the securities of the Issuer.**

BY ORDER OF THE BOARD

DR.PENG HOLDING HONGKONG LIMITED

Dated: 20 January 2023